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Letter to the Editor 
 
Impact of eNOS polymorphisms on red blood cell aggregation in sickle cell disease 
 
To the Editor, 
 
Hemorheological abnormalities have been well characterized in sickle cell disease 
(SCD) and seem to modulate the clinical severity [1]. For instance, increased blood viscosity 
raises the risk for frequent vaso-occlusive crisis (VOC) and increased red blood cell (RBC) 
aggregates robustness (i.e., RBC disaggregation threshold) enhances the risks for acute chest 
syndrome (ACS) [2]. Moreover, patients with the most rigid RBCs are characterized by high 
hemolytic rate, which increases the risks to develop leg ulcers or glomerulopathy [3]. 
However, except few studies supporting an effect of -thalassemia and oxidative stress [1] on 
RBC rheological properties of SCD patients, very few experiments focused on the genetic and 
cellular factors modulating blood rheology in this disease. 
Recently, a growing interest has been devoted to the role of nitric oxide (NO) on blood 
rheology in healthy individuals: NO would improve RBC deformability and decrease RBC 
aggregation [4]. Several variants, namely -786-TC polymorphism (rs2070744), 27 pb-VNTR 
repeat, 894-GT (rs1799983), have been described for the endothelial NO-synthase (eNOS) 
gene. These variants affect both NO production and endothelial function. One could suggest a 
relationship between eNOS polymorphisms, plasma NO content and hemorheological 
characteristics. This hypothesis is supported by the findings of Fatini et al. [5] who found an 
association between eNOS polymorphisms and RBC rheological properties (i.e. aggregation 
and deformability) in healthy individuals. However, such phenotype/genotype relationship 
has never been studied in SCD. The aim of the present study was to highlight eNOS 
polymorphisms effect on hemorheological parameters and NO levels in SCD. 
 
SCD patients followed at the Sickle Cell Unit of Guadeloupe were included: 110 
children (8-16 yrs old) and 131 adults (i.e. ≥ 18 yrs old); 138 with homozygous SCD and 103 
with sickle cell hemoglobin C disease. The study was approved by the Regional Ethics 
Committee (DIRC Sud/Ouest Bordeaux/DOM, registration number: 2009-A00211-
56/SAPOTILLE and 2010-A00244-35/HTA projects). All patients provided written informed 
consent and were at steady state (i.e. no blood transfusion or acute events in the previous three 
months). Hemorheological parameters were measured as previously described [2]. Plasma NO 
metabolites (NOx) level was measured in the pediatric cohort [6]. Genomic DNA was 
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extracted from peripheral blood leukocytes and genotyped using PCR-based methods. Mann–
Whitney/Kruskal–Wallis tests were used to compare each parameter between patients 
classified according to eNOS genotypes. Known parameters affecting hemorheological 
properties such as age, SCD genotype and hydroxycarbamide treatment were included as 
covariates in a linear regression model. A p < 0.05 value was considered significant.  
 
Baseline characteristics of sickle cell patients for clinical, biological, and 
hemorheological parameters are presented in Table 1. The genotypic and allelic distributions 
for three polymorphic variants of the eNOS gene (i.e., VNTR-27pb, 894G>T and -786T>C) 
are also summarized. The homozygous wild types occur at higher frequency for VNTR-55, -
786-TT and 894-GG polymorphisms, respectively (43.7 %, 69.8 %, 84.2 %). The lower 
frequencies were found for the homozygous mutants: 0.4 % for VNTR-66, 0.4 % for -786-
CC, and 0.9 % for 894-GG. 
The RBC disaggregation threshold was significantly lower in individuals with VNTR-
56 or 66 genotypes compared to 55 or 45 genotypes (Table 2). Linear regression analysis 
revealed that VNTR polymorphisms significantly affected the RBC disaggregation threshold 
variability (p = 0.039) independently of age (p = 0.647), SCD genotype (p = 0.324) and 
hydroxycarbamide treatment (p = 0.249). No relationship was detected between eNOS 
polymorphisms and the other parameters. Although, the 27 pb-VNTR variant harboring 4 
copies in intron 4 acts as a cis-acting regulator of eNOS expression and was previously found 
to be associated with a decreased eNOS expression and NO plasma level [7], this study did 
not detect any association between eNOS polymorphisms and NOx level in the pediatric 
cohort. These unexpected results need to be confirmed in larger cohorts of SCD patients but 
one may underline that chronic hemolysis might have affected plasma NOx level too [8]. 
 
We demonstrated for the first time an impact of eNOS 27 bp-VNTR polymorphism on 
the RBC disaggregation threshold variability in a large cohort of SCD patients. It is 
worthwhile to notice that faster RBC aggregation was previously described in subjects with 
the VNTR-44 or 45 genotype compared to those with the VNTR-55 genotype [9]. Altogether, 
these data suggest that the VNTR polymorphism modulate RBC aggregation properties. 
These findings may be of clinical relevance since it has been previously demonstrated that 
increased RBC aggregates robustness enhances the risks for acute chest syndrome (ACS) [2]. 
Further studies are warranted to test this hypothesis. 
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Table 1. Baseline characteristics of the studied population (n = 241) 
        
C
li
n
ic
al
 d
at
a 
Age (year) 
  mean ± sd 24.8 ± 15.6 
median (iqr) 19 (24) 
Sex, n (%) 
  Men 111 (46.1) 
Women 130 (53.9) 
SCD Status, n (%) 
  SS 138 (57.3) 
SC 103 (42.7) 
HU
a
 treatment, n (%) 
  treated 33 (13.7) 
non-treated 208 (86.3) 
B
io
lo
g
ic
al
 
p
ar
am
et
er
s NOx
b 
(µmol.l
-1
)     
mean  ± sd 30.8 ± 10.4 
H
em
o
rh
eo
lo
g
ic
al
 p
ar
am
et
er
s 
 
EI
c
 (a.u.)     
mean ± sd 0.396 ±  0.1 
median (iqr) 0.408 (0.131) 
AI
d
 (%)  
  mean ± sd 49.3 ± 9.8 
γe (s-1) 
  mean ± sd 282.3 ±  112.9 
median (iqr) 275 (155) 
Blood viscosity (cP) mean ± sd 
  225s  6.3 ±  1.4 
90s  8.2 ±  2.3 
eN
O
S
 P
o
ly
m
o
rp
h
is
m
s 
 
VNTR, n (%) 
  44 21 (8.8) 
45 101 (42.1) 
55 105 (43.7) 
56 12 (5.0) 
66 1 (0.4) 
-786TC, n (%) 
  TT 162 (69.8) 
TC 69 (29.8) 
CC 1 (0.4) 
894GT, n (%) 
  GG 198 (84.2) 
GT 35 (14.9) 
TT 2 (0.9) 
aHydroxyurea, bNitric oxide end-products, cElongation Index (i.e., RBC deformability), dRBC 
Aggregation Index, eRBC Disaggregation threshold 
SCD patients: sickle cell anemia patients (138) and sickle cell hemoglobin C patients (103) ; 
VNTR: variable number of tandem DNA repeats 
  Quantitative data are expressed as mean (± standard deviation/±sd) or median (interquartile range/iqr) 
  Qualitative date are expressed as number (percentage/%) 
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Table 2. Descriptive statistics of biological and hemorheological parameters according to eNOS polymorphisms 
  
                                        
 
NOx
a
 
Blood viscosity 
225 s
-1
 
Blood viscosity  
90 s
-1
 EI
b
  AI
c
 γd  
 
(µmol.l
-1
)  (mPa.s
-1
)  (cP) 
 
(au) 
 
   (%)    
 
(s
-1
) 
 
  n mean ± sd n mean ± sd n mean ± sd n mean ± sd n mean ± sd n mean ± sd 
VNTR       
   
      
   
      
   44 + 45 54 30.5 ± 9.8 116 6.4 ± 1.4 118 8.4 ± 2.3 120 0.400 ± 0.1 119 50.4 ± 9.6 119 291.7 ± 121.2 
55 50 31.0 ± 11.4 96 6.2 ± 1.5 95 7.9 ± 2.3 101 0.388 ± 0.1 101 48.3 ± 10.0 101 282.6 ± 104.0 
56 + 66 4 31.2 ± 2.8 13 6.5 ± 1.3 13 8.6 ± 2.2 13 0.406 ± 0.1 13 47.6 ± 9.2 13 208.2 ± 54.3  
p-value*   NS   
 
NS 
 
  NS   
 
NS 
 
  NS   
 
0.015
‡
 
 -786TC                                     
TT 72 31.1 ± 10.0 151 6.3 ± 1.4 152 8.2 ± 2.3 159 0.393 ± 0.1 159 49.0 ± 9.2 159 282.1 ± 110.2 
TC + CC 36 32.1 ± 11.2 67 6.3 ± 1.5 67 8.0 ± 2.3 68 0.401 ± 0.1 67 49.8 ± 11.0 67 286.1 ± 121.7 
p-value*   NS     NS     NS     NS     NS     NS   
894GT       
   
      
   
      
   GG 91 30.7 ± 10.2 186 6.4 ± 1.4 187 8.2 ± 2.3 193 0.396 ± 0.1 193 49.3 ± 9.7 193 284.8 ± 117.8 
GT + TT 17 31.2 ± 11.9 34 6.1 ±1.5 34 8.0 ± 2.4 36 0.396 ± 0.1 35 48.1 ± 11.0 35 271.8 ± 90.0 
p-value*   NS     NS     NS     NS     NS     NS   
a
Nitric oxide end-products measured in the pediatric cohort only, 
b
Elongation Index (i.e., RBC deformability), 
c
Red blood cell 
Aggregation Index, 
d
Red blood cell disaggregation threshold.  
*by univariate analysis  
‡
p value = 0.039 for RBC disaggregation threshold adjusted for age, SCD status and HC treatment (multivariate analysis)
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